The Cladribine Multiple Sclerosis pill to be known as Mylinax is approved for use in the US for treating forms of blood cell cancer under the brand name Leustatin.  But while approved in some countries, Cladribine MS use in the states has met repeated rejection by the FDA.  The reason so many patients are excited about Cladribine Multiple Sclerosis approval is that it will be in the form of a pill.  There is still no cure for MS, but a lot of research is being conducted to focus on easing the symptoms and slowing the disability.  There are estimate that over two million patients worldwide suffer from MS, most from the relapsing-remitting form of the disease. If approval is won in the US for Cladribine, Multiple Sclerosis would certainly celebrate, but Merck would stand to gain financially in a substantial way as well.  So they are not about to give …